RY764
RY746 is a selective MC4R agonist, with an EC50 of 10 nM. RY764 effectively inhibits food intake and reduces body weight gain in diet-induced obese (DIO) rat models. RY764 can be used for the study of obesity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 491845-95-5
- 分子式: C34H51FN4O3
- 分子量:582.79
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
MC4R 10 nM (EC50) |
MC3R 70 nM (EC50) |
MC1R 580 nM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
160 μM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 1 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 1 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | IC50 |
3 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against mouse melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against mouse melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
3 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against rat melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against rat melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
7 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against dog melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against dog melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
750 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 1 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 1 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | EC50 |
11 nM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | EC50 |
11 μM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | EC50 |
850 nM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | EC50 |
850 μM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | IC50 |
>10000 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 2 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 2 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
8 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
8 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
942 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
942 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
945 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
945 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
化学情報
-
CAS 番号 491845-95-5
-
分子量 582.79
-
分子式 C34H51FN4O3
-
SMILES
CC(C)(C)NC(C1(C2CCCCC2)CCN(CC1)C([C@H](NC([C@H]3[C@]4([H])N(C[C@](CC4)([H])C3)C)=O)CC5=CC=C(C=C5)F)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)